Evidence map›Paper›PMID 29438037›Full record

ArticleNeurology2018

Tau-negative amnestic dementia masquerading as Alzheimer disease dementia.

Hugo Botha, William G Mantyh, Jonathan Graff-Radford, Mary M Machulda, Scott A Przybelski, Heather J Wiste, Matthew L Senjem, Joseph E Parisi, Ronald C Petersen, Melissa E Murray and 5 more

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Neurology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.

0numbers the graph read from it
0cells of the map it votes in
28citing papers in PubMed
2.4field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

28 citing papers in PubMed, 38 citations in OpenAlex.

  1. Trial
  2. Clinical and molecular correlates of limbic age-related TDP-43 encephalopathy (LATE)European journal of nuclear medicine and molecular imaging · 2025
    Article
  3. Article
  4. Antiamyloid Monoclonal Antibodies in Alzheimer's Disease, Part 1: Patient Selection.The Journal of neuropsychiatry and clinical neurosciences · 2025
    Article
  5. Precision diagnosis of cognitive impairment due to Alzheimer's disease for therapeutic interventions.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025
    Review
  6. Review
  7. Revised criteria for diagnosis and staging of Alzheimer's disease: Alzheimer's Association Workgroup.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2024
    Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Posterior Cingulate Involvement Does Not Argue Against LATE.Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2022
    Article
  14. Article
  15. Article
  16. Article
  17. International consensus on the use of tau PET imaging agentEuropean journal of nuclear medicine and molecular imaging · 2022
    Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 1 institution in 2 countries.

Hugo BothaFrom the Departments of Neurology (H.B., W.G.M., J.G.-R., R.C.P., B.F.B., D.S.K., D.T.J.), Psychiatry and Psychology (M.M.M.), Radiology (S.A.P., H.J.W., M.L.S., C.R.J., D.T.J.), Pathology (J.E.P.), and Nuclear Medicine (V.J.L.), Mayo Clinic, Rochester, MN; and Department of Neuroscience (M.E.M.), Mayo Clinic, Jacksonville, FL.
William G MantyhFrom the Departments of Neurology (H.B., W.G.M., J.G.-R., R.C.P., B.F.B., D.S.K., D.T.J.), Psychiatry and Psychology (M.M.M.), Radiology (S.A.P., H.J.W., M.L.S., C.R.J., D.T.J.), Pathology (J.E.P.), and Nuclear Medicine (V.J.L.), Mayo Clinic, Rochester, MN; and Department of Neuroscience (M.E.M.), Mayo Clinic, Jacksonville, FL.
Jonathan Graff-RadfordFrom the Departments of Neurology (H.B., W.G.M., J.G.-R., R.C.P., B.F.B., D.S.K., D.T.J.), Psychiatry and Psychology (M.M.M.), Radiology (S.A.P., H.J.W., M.L.S., C.R.J., D.T.J.), Pathology (J.E.P.), and Nuclear Medicine (V.J.L.), Mayo Clinic, Rochester, MN; and Department of Neuroscience (M.E.M.), Mayo Clinic, Jacksonville, FL.
Mary M MachuldaFrom the Departments of Neurology (H.B., W.G.M., J.G.-R., R.C.P., B.F.B., D.S.K., D.T.J.), Psychiatry and Psychology (M.M.M.), Radiology (S.A.P., H.J.W., M.L.S., C.R.J., D.T.J.), Pathology (J.E.P.), and Nuclear Medicine (V.J.L.), Mayo Clinic, Rochester, MN; and Department of Neuroscience (M.E.M.), Mayo Clinic, Jacksonville, FL.
Scott A PrzybelskiFrom the Departments of Neurology (H.B., W.G.M., J.G.-R., R.C.P., B.F.B., D.S.K., D.T.J.), Psychiatry and Psychology (M.M.M.), Radiology (S.A.P., H.J.W., M.L.S., C.R.J., D.T.J.), Pathology (J.E.P.), and Nuclear Medicine (V.J.L.), Mayo Clinic, Rochester, MN; and Department of Neuroscience (M.E.M.), Mayo Clinic, Jacksonville, FL.
Heather J WisteFrom the Departments of Neurology (H.B., W.G.M., J.G.-R., R.C.P., B.F.B., D.S.K., D.T.J.), Psychiatry and Psychology (M.M.M.), Radiology (S.A.P., H.J.W., M.L.S., C.R.J., D.T.J.), Pathology (J.E.P.), and Nuclear Medicine (V.J.L.), Mayo Clinic, Rochester, MN; and Department of Neuroscience (M.E.M.), Mayo Clinic, Jacksonville, FL.
Matthew L SenjemFrom the Departments of Neurology (H.B., W.G.M., J.G.-R., R.C.P., B.F.B., D.S.K., D.T.J.), Psychiatry and Psychology (M.M.M.), Radiology (S.A.P., H.J.W., M.L.S., C.R.J., D.T.J.), Pathology (J.E.P.), and Nuclear Medicine (V.J.L.), Mayo Clinic, Rochester, MN; and Department of Neuroscience (M.E.M.), Mayo Clinic, Jacksonville, FL.
Joseph E ParisiFrom the Departments of Neurology (H.B., W.G.M., J.G.-R., R.C.P., B.F.B., D.S.K., D.T.J.), Psychiatry and Psychology (M.M.M.), Radiology (S.A.P., H.J.W., M.L.S., C.R.J., D.T.J.), Pathology (J.E.P.), and Nuclear Medicine (V.J.L.), Mayo Clinic, Rochester, MN; and Department of Neuroscience (M.E.M.), Mayo Clinic, Jacksonville, FL.
Ronald C PetersenFrom the Departments of Neurology (H.B., W.G.M., J.G.-R., R.C.P., B.F.B., D.S.K., D.T.J.), Psychiatry and Psychology (M.M.M.), Radiology (S.A.P., H.J.W., M.L.S., C.R.J., D.T.J.), Pathology (J.E.P.), and Nuclear Medicine (V.J.L.), Mayo Clinic, Rochester, MN; and Department of Neuroscience (M.E.M.), Mayo Clinic, Jacksonville, FL.
Melissa E MurrayFrom the Departments of Neurology (H.B., W.G.M., J.G.-R., R.C.P., B.F.B., D.S.K., D.T.J.), Psychiatry and Psychology (M.M.M.), Radiology (S.A.P., H.J.W., M.L.S., C.R.J., D.T.J.), Pathology (J.E.P.), and Nuclear Medicine (V.J.L.), Mayo Clinic, Rochester, MN; and Department of Neuroscience (M.E.M.), Mayo Clinic, Jacksonville, FL.
Bradley F BoeveFrom the Departments of Neurology (H.B., W.G.M., J.G.-R., R.C.P., B.F.B., D.S.K., D.T.J.), Psychiatry and Psychology (M.M.M.), Radiology (S.A.P., H.J.W., M.L.S., C.R.J., D.T.J.), Pathology (J.E.P.), and Nuclear Medicine (V.J.L.), Mayo Clinic, Rochester, MN; and Department of Neuroscience (M.E.M.), Mayo Clinic, Jacksonville, FL.
Val J LoweFrom the Departments of Neurology (H.B., W.G.M., J.G.-R., R.C.P., B.F.B., D.S.K., D.T.J.), Psychiatry and Psychology (M.M.M.), Radiology (S.A.P., H.J.W., M.L.S., C.R.J., D.T.J.), Pathology (J.E.P.), and Nuclear Medicine (V.J.L.), Mayo Clinic, Rochester, MN; and Department of Neuroscience (M.E.M.), Mayo Clinic, Jacksonville, FL.
David S KnopmanFrom the Departments of Neurology (H.B., W.G.M., J.G.-R., R.C.P., B.F.B., D.S.K., D.T.J.), Psychiatry and Psychology (M.M.M.), Radiology (S.A.P., H.J.W., M.L.S., C.R.J., D.T.J.), Pathology (J.E.P.), and Nuclear Medicine (V.J.L.), Mayo Clinic, Rochester, MN; and Department of Neuroscience (M.E.M.), Mayo Clinic, Jacksonville, FL.
Clifford R JackFrom the Departments of Neurology (H.B., W.G.M., J.G.-R., R.C.P., B.F.B., D.S.K., D.T.J.), Psychiatry and Psychology (M.M.M.), Radiology (S.A.P., H.J.W., M.L.S., C.R.J., D.T.J.), Pathology (J.E.P.), and Nuclear Medicine (V.J.L.), Mayo Clinic, Rochester, MN; and Department of Neuroscience (M.E.M.), Mayo Clinic, Jacksonville, FL.
David T JonesFrom the Departments of Neurology (H.B., W.G.M., J.G.-R., R.C.P., B.F.B., D.S.K., D.T.J.), Psychiatry and Psychology (M.M.M.), Radiology (S.A.P., H.J.W., M.L.S., C.R.J., D.T.J.), Pathology (J.E.P.), and Nuclear Medicine (V.J.L.), Mayo Clinic, Rochester, MN; and Department of Neuroscience (M.E.M.), Mayo Clinic, Jacksonville, FL. Jones.david@mayo.edu.
Jacksonville College · US

Funding

THE PGRN/TDP-43 AXIS IN ALZHEIMER?S DISEASE AND NEURODEGENERATIONP50AG016574 · NIA · MAYO CLINIC ROCHESTER · PI VEMURI, PRASHANTHI · 1999 to 2018
$36.9M
PREDICTING ALZHEIMERS DISEASE WITH MAGNETIC RESONANCER01AG011378 · NIA · MAYO CLINIC ROCHESTER · PI JACK, CLIFFORD R. · 1993 to 2017
$12.1M
Disease pathways in the population determined by amyloid, tau, and neurodegeneration imaging biomarkersR37AG011378 · NIA · MAYO CLINIC ROCHESTER · PI CLIFFORD R. JACK · 2018 to 2026
$6.8M
Validating the New Criteria for Preclinical Alzheimer's diseaseR01AG041851 · NIA · MAYO CLINIC ROCHESTER · PI JACK, CLIFFORD R., KNOPMAN, DAVID S · 2012 to 2021
$6.3M
Clinicopathologic and Neuroimaging Differences in Alzheimer's Disease VariantsR01AG054449 · NIA · MAYO CLINIC JACKSONVILLE · PI MURRAY, MELISSA ERIN · 2017 to 2021
$3.9M
NIA NIH HHS P50 AG016574NIA NIH HHS R01 AG011378NIA NIH HHS R01 AG041851NIA NIH HHS R37 AG011378
6 · The paper itself

Abstract

objectiveTo describe the phenomenon of tau-negative amnestic dementia mimicking Alzheimer disease (AD) clinically and radiologically and to highlight the importance of biomarkers in AD research.

methodsEight participants with amnestic mild cognitive impairment or AD dementia were evaluated by a behavioral neurologist and had a standardized neuropsychological battery performed. All participants completed structural (MRI) and molecular (amyloid and tau PET) imaging. AD-signature thickness and adjusted hippocampal volume served as structural biomarkers, while standardized uptake value ratios (SUVRs) from validated regions of interest for amyloid and tau PET were used to determine molecular biomarker status.

resultsAll participants were thought to have AD as the primary driver of their symptoms before any PET imaging. All participants had hippocampal atrophy, and 2 participants fell below the AD-signature thickness cutoff for elderly controls (2.57), with a further 3 falling below the more stringent cutoff based on young controls (2.67). Four participants were amyloid positive (SUVR >1.42), and all were tau negative (SUVR <1.33).

conclusionsThe participants presented here were clinically impaired, with structural imaging evidence of neurodegeneration, in the absence of any significant tau accumulation. Therefore, AD is unlikely as a cause of their clinical presentation and neurodegenerative imaging findings. Several implications are discussed, including the need to establish amyloid and tau positivity in N+ participants before enrolling them in trials of disease-modifying therapy agents for AD.

Indexed as

AgedAged, 80 and overAmnesiaAniline CompoundsAtrophyBrainCarbolinesCognitive DysfunctionDementiaDiagnosis, DifferentialFemaleHumansMagnetic Resonance ImagingMaleNeuropsychological TestsOrgan Size2-(4'-(methylamino)phenyl)-6-hydroxybenzothiazole7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indoleAniline CompoundsCarbolinesMAPT protein, humanRadiopharmaceuticalstau ProteinsThiazoles

Identifiers

PMID29438037
PMCPMC5858947
OpenAlexW2786425460

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.